EMEA-001855-PIP01-15-M05

Opinion/decision on a Paediatric investigation plan (PIP): Kyprolis, carfilzomib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Haematology-Hemostaseology;Oncology, PIP number: P/0408/2023

EMEA-002243-PIP01-17-M04

EMEA-002519-PIP03-21-M01

Opinion/decision on a Paediatric investigation plan (PIP): Briviact (in Italy: Nubriveo), Brivaracetam, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Neurology, PIP number: P/0398/2023

Opinion/decision on a Paediatric investigation plan (PIP): Xerava, eravacycline, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infectious diseases, PIP number: P/0397/2023

Opinion/decision on a Paediatric investigation plan (PIP): Dupixent, dupilumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Dermatology, PIP number: P/0396/2023

Human medicines European public assessment report (EPAR): Praxbind, idarucizumab, Date of authorisation: 20/11/2015, Revision: 13, Status: Authorised

PSUSA/00000166/202312

Veterinary medicines European public assessment report (EPAR): Fevaxyn Pentofel, inactivated feline panleukopenia virus, calicivirus, rhinotracheitis virus, leukaemia virus and Chlamydophila felis, Status: Withdrawn (authorisation)